Please assess the completion status of the following clinical trial:

Trial Title: Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (for the selection part):~* Inoperable or metastatic soft tissue sarcoma and/or uterine sarcoma~* Measurable lesions (RECIST 1.1)~* Performance status ≤ 2~* Age ≥ 18~* Normal hematological parameters (polynuclear neutrophils ≥ 1500, hemoglobin level ≥ 9 g/dl, platelets counts ≥ 100,000)~* Adequate biological parameters :~* Adequate hepatic function (bilirubin ≤ ULN , SGPT/ALT and SGOT/AST ≤ 2.5 x ULN)~* Alkaline phosphatases ≤ 2.5 x ULN, If Alkaline phosphatases ≥ 2.5 ULN, hepatic isoenzymes 5-nucleotidases or GGT tests must be performed; hepatic isoenzymes 5- nucleotidases and/or GGT must be within the normal range~* Albumin ≥ 25 g/L~* Adequate renal function : Serum creatinine ≤ 1.5 x ULN~* Creatine phosphokinase ≤ 2.5 x ULN~* Adequate central venous access~* Pregnant or lactating women or men of reproductive potential must use effective contraceptive methods~* Patient covered by government health insurance~* Information sheet given to the patient (Patient information sheet 1)~Exclusion Criteria (for the selection part):~* Patients that have received more than one regimen of chemotherapy for metastatic or inoperable soft tissue or uterine sarcoma, after the failure/intolerance of doxorubicin and ifosfamide. Maintenance treatment does not count as treatment line~* The following histological subtypes : GIST, rhabdomyosarcoma, aggressive fibromatosis, desmoïd tumour, PNET, carcinosarcoma, and all bone sarcomas~* Single tumour in an irradiated region~* Other malignant tumour over the past five years (except basal cell carcinoma or cervical carcinoma in situ adequately treated)~* Currently active bacterial or fungus infection (\> grade 2 CTC \[CTCAE\] Version 4.02). Known HIV1, HIV2, hepatitis B or hepatitis C infections~* Presence of known leptomeningeal or brain metastasis~* Patients unable to receive corticotherapy~* Any circumstance that could jeopardise compliance or proper follow-up during the trial~* Pregnant or nursing women~Inclusion Criteria (for the randomized part):~* Patient registered in the selection part~* Stable tumour or objective response (CR + PR) after 6 Trabectedin (Yondelis®) cycles, according to local assessment~* Available copies of thoraco-abdominal and pelvic scan performed prior to the first cycle and after the sixth cycle~* Performance status ≤ 2~* Patients receiving at least 1 mg/m²/3 weeks of Trabectedin at the time of the sixth cycle~* Normal hematological parameters (polynuclear neutrophils ≥ 1500, hemoglobin level ≥ 9 g/dl, platelets counts ≥ 100,000)~* Adequate biological parameters :~* Adequate hepatic function (bilirubin ≤ ULN , SGPT/ALT and SGOT/AST ≤ 2.5 x ULN)~* Alkaline phosphatases ≤ 2.5 x ULN, If Alkaline phosphatases ≥ 2.5 ULN, hepatic isoenzymes 5-nucleotidases or GGT tests must be performed; hepatic isoenzymes 5- nucleotidases and/or GGT must be within the normal range~* Albumin ≥ 25 g/L~* Adequate renal function : Serum creatinine ≤ 1.5 x ULN~* Creatine phosphokinase (CPK) ≤ 2.5 x ULN~* Adequate central venous access~* Pregnant or lactating women or men of reproductive potential must use effective contraceptive methods~* Informed consent form signed by the patient or the patient's legal representative (patient information sheet 2 and informed consent)~Exclusion Criteria (for the randomized part):~* Tumour progression (according to RECIST 1.1) during the first six Yondelis cycles~* Non-availability of baseline scans prior to the first cycle and following the sixth cycle~* Currently active bacterial or fungus infection (\> grade 2 CTC \[CTCAE\] Version 4.02). Known HIV1, HIV2, hepatitis B or hepatitis C infections~* Presence of known leptomeningeal or brain metastasis~* Creatinine clearance less than 30 ml/min~* Patients unable to receive corticotherapy~* Any circumstance that could jeopardise compliance or proper follow-up during the trial~* Pregnant or nursing women~* Hypersensitivity to Trabectedin or any excipient in prior cycles

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuation of Trabectedin (Type: OTHER): patient receives 6 cycles of trabectedin, then one dose 15 days after the 6th cycle, every 3 weeks until progression/ toxicity
- Drug holiday therapy (Type: OTHER): patient receives 6 cycles of trabectedin, then one dose 15 days after the 6th cycle and he stops the drug until progression and re-challenge

Based on this trial design, predict the completion outcome and termination type (if applicable).